Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
Drug guidance

Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma

Condition

Cancer

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combination with chemotherapy for inclusion on the MOH List of Subsidised Drugs for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma. The decision was based on the unfavourable cost-effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for toripalimab plus chemotherapy are provided in the Annex.

Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma (Published 16 Sep 2025) [PDF, 204 KB]

PES Toripalimab for treating recurrent or metastatic nasopharyngeal carcinoma (Published 16 Sep 2025) [PDF, 63 KB]

Back to top